In cooperation between the FLI and AbbVie Inc., we test the in vivo efficacy of monoclonal antibodies and small molecules raised against the SARS-CoV-2 spike protein. The project which is based on an agreement is focused on alternative delivery of respective development candidates to support systemic treatment or as a stand-alone therapy.
For other candidates, in vitro data will be generated in alignment between AbbVie Inc. and FLI prior to in vivo testing in the Syrian Hamster SARS-CoV-2 model that has recently been established and validated at the FLI.
Furthermore, there is agreement to evaluate also potential therapeutic possibilities for other relevant infectious agents in the future.
